<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03764631</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0149</org_study_id>
    <nct_id>NCT03764631</nct_id>
  </id_info>
  <brief_title>Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration</brief_title>
  <official_title>Post-authorization Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration Among Patients Treated With Empagliflozin or DPP-4 Inhibitors in Saudi Arabia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract
      infections, volume depletion, and dehydration associated in patients with T2DM initiating
      Empagliflozin compared to patient initiating a dipeptidyl peptidase-4 (DPP-4) inhibitors over
      a 12-month period of follow-up, including the month of Ramadan
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>subjects with incidence of Ketoacidosis</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>subjects with incidence of severe urinary tract infections</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>subjects with incidence of volume depletion</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>subjects with incidence of dehydration</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>subjects with risk of ketoscidosis in The Ramadan period</measure>
    <time_frame>Up to day 29</time_frame>
    <description>1st day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjects with risk of severe urinary tract infections in The Ramadan period</measure>
    <time_frame>Up to day 29</time_frame>
    <description>1st day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjects with risk of volume depletion in The Ramadan period</measure>
    <time_frame>Up to day 29</time_frame>
    <description>1st day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjects with risk of dehydration in The Ramadan period</measure>
    <time_frame>Up to day 29</time_frame>
    <description>1st day of Ramadan to 29th day of Ramadan based on the Islamic Hijri calendar)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>subjects with Type 2 Diabetes mellitus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Drug</description>
    <arm_group_label>subjects with Type 2 Diabetes mellitus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl-peptidase 4 (DPP-4) inhibitors</intervention_name>
    <description>Dipeptidyl-peptidase 4 - Drug</description>
    <arm_group_label>subjects with Type 2 Diabetes mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Main diagnosis for study entry

        -Patients diagnosed with T2DM will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have signed Informed consent form.

          -  The patients will be at least 18 years old at index date, diagnosed with Type 2
             diabetes mellitus (T2DM) in Saudi Arabia, and who will initiate Empagliflozin or
             Dipeptidyl-peptidase 4 (DPP4) inhibitors treatment according to the local label and at
             the discretion of the treating physician during the study period, who have not used
             other sodium/glucose co-transporter 2 (SGLT2) or DPP4 inhibitors during the previous
             12 months.

        Exclusion Criteria:

          -  Known hypersensitivity to Empagliflozin, the comparator DPP-4 inhibitors or any of
             their excipients

          -  Patients for whom Empagliflozin or the comparator DPP-4 inhibitor is contraindicated
             according Saudi Food and Drug Authority (SFDA) approved label

          -  Patients prescribed fixed-dose combinations of SGLT2 inhibitors with DPP-4 inhibitors
             will be excluded.

          -  The same inclusion and exclusion criteria will be applied to the comparator group,
             which will include new users of DPP-4 inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Mansour, +201028866717</last_name>
    <role>Study Chair</role>
    <affiliation>ahmed.mansour@boehringer-ingelheim.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abha International Private Hospital</name>
      <address>
        <city>Abha</city>
        <zip>61431</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DAFA Special Polyclinic</name>
      <address>
        <city>Jeddah</city>
        <zip>21214</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghassan Najeeb Pharaon Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21412</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center</name>
      <address>
        <city>Jeddah</city>
        <zip>21451</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.Bakhsh Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21452</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Soliman Fakeeh Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21461</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saudi German Hospital</name>
      <address>
        <city>Jeddah</city>
        <zip>21461</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Abeer Medical Center</name>
      <address>
        <city>Jeddah</city>
        <zip>21573</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Abeer Medical Center</name>
      <address>
        <city>Jeddah</city>
        <zip>21573</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Abeer Polyclinic</name>
      <address>
        <city>Jeddah</city>
        <zip>23531</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Rahman Polyclinic</name>
      <address>
        <city>Makkah</city>
        <zip>24232</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shifa Hospital</name>
      <address>
        <city>Makkah</city>
        <zip>24232</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Noor Specialist Hospital</name>
      <address>
        <city>Makkah</city>
        <zip>24241</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Zafer Hospital</name>
      <address>
        <city>Najran</city>
        <zip>66261</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obesity, Endocrine and Metabolism Center</name>
      <address>
        <city>Riyadh</city>
        <zip>11525</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riyadh Medical Center</name>
      <address>
        <city>Riyadh</city>
        <zip>11533</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alalam Medical Center</name>
      <address>
        <city>Riyadh</city>
        <zip>13214</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Fahad bin Sultan hospital</name>
      <address>
        <city>Tabuk</city>
        <zip>47311</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Hada Armed Forces Hospital</name>
      <address>
        <city>Taif</city>
        <zip>21944</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al Amal Medical Group</name>
      <address>
        <city>Yanbu</city>
        <zip>46455</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alansari Specialist Hospital</name>
      <address>
        <city>Yanbu</city>
        <zip>46455</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

